Improving the retroviral vector (RV) systems for immunotherapy of cancer.
Grabarczyk
P
P
Department of Cancer Immunology, University School of Medical Sciences, GreatPoland Cancer Center, Poznań, Poland.
Gryska
K
K
Wysocki
P J
PJ
Izycki
D
D
Mackiewicz
A
A
D002292:Carcinoma, Renal Cell / Q000235:genetics / Q000276:immunology / Q000628:therapy; D015870:Gene Expression; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007680:Kidney Neoplasms / Q000235:genetics / Q000276:immunology / Q000628:therapy; D008545:Melanoma / Q000235:genetics / Q000276:immunology / Q000628:therapy; D009369:Neoplasms / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012334:RNA, Neoplasm / Q000235:genetics / Q000378:metabolism; D011991:Receptors, Virus / Q000235:genetics; D012190:Retroviridae / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014407:Tumor Cells, Cultured
D012333:RNA, Messenger; D012334:RNA, Neoplasm; D011991:Receptors, Virus; C067981:leukemia virus receptor, gibbon ape